Diligence memo · auto-generated · as of July 2, 2026

HyperBranch Medical Technology Inc

HyperBranch Medical Technology Inc looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

HyperBranch Medical Technology Inc operates in Other Health Care, based in DURHAM.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

HyperBranch Medical Technology Inc has raised $12M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.1M on 2010-04-01.

Most recent recorded round closed around 2013-04-30.

Valuation (modeled)modeled

Provath models HyperBranch Medical Technology Inc at approximately $12M (range $423K–$97M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.29× the median modeled value of Seed Other Health Care companies in 2013–2015 (251 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 7 months.

Last raise 13.2 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 3.9× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 78% of Other Health Care peers (5377 compared).

Modeled value ranks above 39% of those peers.

Closest niche peers: RightCare Solutions, Inc., Vios Medical, Inc., HealthEdge Investors DD Holdings, LLC, Center at Northridge, LLC, Fresenius Medical Care NKDHC, LLC.

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.